Top of this page
Skip navigation, go straight to the content Innovation Pipeline

R&D pipeline

The UCB pipeline delivers:

  •  a promising portfolio targeting severe diseases and addressing unmet medical needs
  •  focus on neurological and immunological diseases
  • more convenient and effective treatments for patients and specialists.

UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Small molecule drug / NCE


Antibody-based drug / NBE


  Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritis
phase 3 half
 hidradenitis suppurativa
phase 3 half
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 half
 chronic inflammatory demyelinating polyneuropathy (CIDP)phase 2 half
zilucoplan (C5)myasthenia gravisphase 3 half
 immune-mediated necrotizing myopathy (IMNM)phase 2 half
 amyotrophic lateral sclerosis1phase 2 half
 COVID-associated acute respiratory distress syndrome (ARDS)2phase 2 half
Staccato® alprazolamactive epileptic seizurephase 2
dapirolizumab pegol (CD40L)systemic lupus erythematosus3phase 2
UCB0107 (Tau)progressive supranuclear palsy (PSP)phase 1
1 Project phase 1 half
1 Project phase 1 half

1 In partnership with HEALEY ALS Platform Trial
2 In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
3 In partnership with Biogen

Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.